54.32
2.60%
-1.45
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$55.77
Offen:
$55.88
24-Stunden-Volumen:
11.19M
Relative Volume:
1.06
Marktkapitalisierung:
$110.17B
Einnahmen:
$46.51B
Nettoeinkommen (Verlust:
$-6.54B
KGV:
13.79
EPS:
3.94
Netto-Cashflow:
$12.95B
1W Leistung:
+4.62%
1M Leistung:
+2.68%
6M Leistung:
+22.87%
1J Leistung:
+5.93%
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
2023-10-20 | Fortgesetzt | UBS | Neutral |
2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
2023-03-06 | Eingeleitet | Jefferies | Hold |
2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
2021-12-17 | Eingeleitet | Goldman | Buy |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
2021-11-01 | Herabstufung | Argus | Buy → Hold |
2021-07-27 | Fortgesetzt | Truist | Buy |
2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-04-13 | Hochstufung | Truist | Hold → Buy |
2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
2020-09-29 | Eingeleitet | Berenberg | Buy |
2020-07-28 | Eingeleitet | Raymond James | Outperform |
2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
2020-02-27 | Eingeleitet | Barclays | Equal Weight |
2020-01-06 | Fortgesetzt | Citigroup | Buy |
2019-12-13 | Hochstufung | Argus | Hold → Buy |
2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
2019-05-28 | Eingeleitet | Goldman | Buy |
2019-05-20 | Herabstufung | Argus | Buy → Hold |
2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious - Benzinga
BMS Delivers Q3 Beat, Raises 2024 Guidance Amid Strong Demand for Legacy and Newer Drugs - BioSpace
Bristol-Myers Squibb Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
A promising schizophrenia drug showed mixed results. What does that mean for patients?WGN Radio - WGN Radio - Chicago
December 13th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript - The Motley Fool
Bristol Myers earnings beat expectations, driven by sales of older drugs - Reuters
Bristol Myers earnings beat expectations, driven by sales of older drugs By Reuters - Investing.com
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 - BioSpace
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View - Nasdaq
Bristol Myers Squibb stock rises, Merck moves lower. Here's why. - Yahoo Finance
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit - Benzinga
Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs - PharmaLive
Bristol Myers’s stock pops as earnings top estimates and company raises guidance - MarketWatch
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up - MSN
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings: Revenue Surpasses Estimates at $11.9 Billion, GAAP EPS at $0.60 - GuruFocus.com
Bristol Myers Squibb's Earnings Surpass Expectations With Strong Drug Sales - Finimize
Bristol-Myers raises outlook ahead of consensus after Q3 beat - MSN
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Bristol Myers: Q3 Earnings Snapshot - The Washington Post
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance - MSN
Bristol-Myers Squibb Co. Q3 Profit Decreases, But Beats Estimates - Nasdaq
Bristol-Myers Squibb earnings beat by $0.30, revenue topped estimates - Investing.com South Africa
Bristol Raises Guidance on Demand for Eliquis, New Drugs - BNN Bloomberg
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs - CNBC
Bristol-Myers Squibb Q3 24 Earnings Conference Call At 8:00 AM ET - Nasdaq
Areas of interest - Bristol Myers Squibb
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Drugmakers urge appeals court to revive challenge to US drug price negotiation program - Reuters
Bristol Myers Squibb Q3 2024 Earnings Preview: Profit decline anticipated - MSN
Is Eli Lilly Stock a Buy? - The Motley Fool
Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is ‘Too Low’ - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings? - MSN
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts? - Yahoo Finance
UTSA announces partnership with Bristol Myers Squibb to advance pharmaceutical discoveries and development - The University of Texas at San Antonio
Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 - StockTitan
Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - Simply Wall St
Psoriasis around the world - Bristol Myers Squibb
Allspring Global Investments Holdings LLC Has $11.12 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Second Circuit Weighs Whether Bristol-Myers Delayed Cancer Drug - Bloomberg Law
Citigroup downgrades Bristol-Myers Squibb to 'neutral' - XM
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
People and business resource groups - Bristol Myers Squibb
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):